Introduction
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited heart muscle disease characterized by ventricular arrhythmias, an increased risk of sudden death, and predominant right ventricular dysfunction. 1 The pathological hallmark of ARVD/C is myocyte loss with fibro-fatty production. Since the first case series in 1982, [2] [3] [4] our understanding of its pathogenesis, clinical manifestations, and long-term outcomes has advanced significantly. Arrhythmogenic right ventricular dysplasia/cardiomyopathy was initially considered to be a congenital defect in the right ventricular myocardium and designated as dysplasia but later was reclassified as a cardiomyopathy. 5 While involvement of the right ventricle typically predominates in early disease, biventricular, and left dominant forms are now recognized to be an important part of the disease spectrum. 6 The purpose of this review article is to provide an update concerning the diagnosis and treatment strategies in ARVD/C.
Epidemiology
Arrhythmogenic right ventricular dysplasia/cardiomyopathy is a rare condition 7 and has an estimated prevalence of 1:5000. 8 Arrhythmogenic right ventricular dysplasia/cardiomyopathy patients typically present in the 2nd to 4th decade of life. [9] [10] [11] Approximately 20% of the patients present after age of 50 years. Late presentation does not confer a benign prognosis. 12 Men are more commonly affected with earlier onset than women and have worse outcomes once diagnosed. [13] [14] [15] This may be explained by sex-related difference in hormone profiles and exercise participation. 16, 17 Genetic basis
Arrhythmogenic right ventricular dysplasia/cardiomyopathy is mainly inherited in an autosomal-dominant pattern with incomplete penetrance and variable expressivity. 18 Autosomal recessive forms have also been described and can be associated with wooly hair and palmoplantar keratoderma, such as in Naxos disease and Carvajal syndrome. 19 The discovery of the genetic basis of Naxos disease identified the first disease-causing gene 20 in ARVD/C. It is located at chromosome 17q21 and encodes plakoglobin (JUP), a desmosomal protein important in cell-to-cell adhesion. This was followed by the discovery of mutations in genes that encode other desmosomal proteins including desmoplakin (DSP), 21 plakophilin-2 (PKP2), 22 desmoglein-2 (DSG2), 23, 24 and desmocolin-2 (DSC2), 25 all of which cause autosomal-dominant forms of ARVD/C. Mutations in genes encoding non-desmosomal proteins have also been identified. Most are associated with other cardiomyopathies and arrhythmia syndrome and represent phenotypic overlap. These include the intermediate filament protein desmin (DES), 26 the cardiac sodium channel-Na v 1.5 (SCN5A), 27 lamin A/C (LMNA) 28 on the nuclear membrane, titin (TTN), 29 phospholamban (PLN), 30 and filamin C (FLNC). 31 Pathogenic variants in genes encoding proteins of the area composita, a-T-Catenin (CTNNA3), 32 and N-cadherin (CDH2), 33 have been identified in a small group of ARVD/C patients with typical right-predominant disease. The pS358L founder mutation in TMEM43, encoding transmembrane protein 43 is common among French Canadian ARVD/C patients. 9 Possible mutations in transforming growth factor beta-3 (TGFB3) 34 have been described but association with ARVD/C remains to be confirmed. Among all the index cases, PKP2 is the most commonly mutated gene (20-46%), followed by DSP (3-15%), DSG2 (3-20%), DSC2 (1-8%), and JUP (<1%). 35, 36 Non-desmosomal genes account for less than 10% of all pathological variants. 35 Attempts have been made to correlate genotypes to phenotypes. Patients with more than 1 mutation (4-16%) have earlier disease onset and worse disease outcomes including arrhythmia, sudden cardiac death, and heart failure. 37, 38 As in Carvajal syndrome, DSP mutations are also associated with left ventricular dysfunction, sometimes referred to as arrhythmogenic left ventricular dysplasia,37,39 Table 1 provides a list of the genes for which ARVD/C-associated diseasecausing mutations have been identified. Novel mutations can be found and registered at www.ARVD/Cdatabase.info. 41 
Pathophysiology
Arrhythmogenic right ventricular dysplasia/cardiomyopathy is hypothesized as a disease of desmosomal dysfunction based on its genetics. This is supported by the remodelling of intercalated disk 42 and loss of desmosomes observed in ultra-structural studies. 43 Desmosomes and gap junctions are responsible for maintaining cell adhesion, signal transduction, and electrical integrity, all of which have been implicated in the disease pathophysiology. Defective desmosomal proteins lead to loss of adhesion between cardiac myocytes followed by inflammation, fibrosis, death, and production by fibrofatty tissue. 20 This may be aggravated by wall stress from physical activity which disproportionately affects right ventricle compared with left ventricle. 44 Besides providing mechanical cell adhesion, desmosomes are also important in intracellular and intercellular signal transduction. 45, 46 Desmosomal alteration redistributes plakoglobin from cell surface to cytosol and nucleus, which suppresses canonical Wnt signalling by competing with b-catenin. 47 It promotes adipogenesis in the heart by increasing adipogenic factors and reducing inhibitors of adipogenesis, which may explain the typical fibroadipocytic production in ARVD/ C. 48, 49 Lipogenesis and apopotosis have been reproduced by induction of adult-like metabolism in an in vitro model generated by patient-specific mutant PKP2 induced pluripotent stem cells-derived cardiomyocytes. 50 Apart from protein relocation, epitope masking has also been reported to cause reduced plakoglobin immunoreactivity in intercalated discs. 51 Desmosomes also maintain electrical integrity by forming a coordinated protein network called 'connexome' at the intercalated disks by interacting with ion channels and gap junctions. 52, 53 Disruption of electrical coupling may explain the increased arrhythmia susceptibility in ARVD/C even before the onset of significant fibrosis and necrosis. 54 The aggregation of voltage-gated sodium channels with cell adhesion molecules and reduced sodium current from desmosomal mutations may explain the phenotypic overlapping between ARVD/C and Brugada syndrome. 55, 56 Clinically, both conditions can manifest as right precordial electrocardiography (ECG) repolarization abnormalities, right ventricular outflow tract (RVOT) conduction disturbances, and ventricular arrhythmias the from right ventricle. 57 Pathologically, fatty infiltration of the myocardium has been reported in both conditions. 58, 59 As a result, ARVD/C and Brugada syndrome might be at the ends of a spectrum of structural myopathies and sodium current deficiency that share a common origin from abnormal connexome. 56 Exercise has been shown to exacerbate phenotypes in mice with ARVD/C associated mutations. 60, 61 In clinical studies, exercise is associated with disease penetrance and ventricular arrhythmia in ARVD/C. 17, 62, 63 On a population level, ARVD/C has also been reported as a leading cause of sudden cardiac death in competitive athletes. 
Clinical manifestations
The presentation of ARVD/C varies considerably, ranging from proband patients with symptoms related to arrhythmia and heart failure to asymptomatic family members diagnosed in the context of cascade screening. Based on experience from referral centres, index patients usually present with palpitations (30-60%), lightheadedness (20%), and syncope (10-30%). 7, 13, 18, 66, 67 These symptoms are in turn linked to the presence of non-sustained or sustained ventricular arrhythmias. Up to 19% of ARVD/C patients present as cardiac arrest. 68 Arrhythmogenic right ventricular dysplasia/cardiomyopathy can occasionally manifest as chest pain accompanied by transient ischaemic electrocardiographic changes and troponin elevation, mimicking acute myocarditis and heart attack. 69 Atypical chest pain may be explained by small vessel disease producing spasm. 70 Although not at the origin of the disease, myocarditis is thought to be a superimposed phenomenon 71, 72 and certain mutations may increase the susceptibility to it in ARVD/C. 39 Three stages have been described in the natural history of ARVD/C. 5, 73 In the initial 'concealed stage', individuals are asymptomatic. There are no or subtle structural changes in the right ventricle. The risk of cardiac arrest occurring in the concealed phase is extremely small but not zero. About 60% of the cardiac arrest victims were asymptomatic before their event. 68 As the disease progresses into the 'clinically overt stage', symptoms emerge as ventricular arrhythmias and morphological abnormalities in the right ventricle appear. Ventricular arrhythmias range from premature ventricular complexes, non-sustained or sustained ventricular tachycardia, and ventricular fibrillation 18 ( Figure 1 ). Atrial arrhythmias and atrial fibrillation have also been associated with ARVD/C, [74] [75] [76] [77] Haemodynamically tolerated ventricular tachycardia has been found in up to 60% of the index patients in their initial presentation. 78 In a subset of patients, the disease may progress to right, left, or biventricular failure. We recently reported that 49% of ARVD/C patients had at least one heart failure symptom, with exertional dyspnoea being more common than volume overload. Among ARVD/C patients with heart failure, approximately 80% have isolated right ventricular dysfunction. Female sex and lateral precordial T-wave inversions have been associated with heart failure. 79 According to experience at Johns Hopkins and the Nordic ARVD/C Registry, heart failure is the most common (90%) indication to heart transplant in ARVD/C 80 and age at first symptoms under 35 years predicts transplantation. 81 Among patients undergoing heart transplant, 58% had biventricular failure, 29% had right ventricular failure, and 3% had left ventricular failure. Sudden cardiac death also occurs at the end of the disease from overt heart failure.
Diagnosis of arrhythmogenic right ventricular dysplasia/ cardiomyopathy 2010 Task Force Criteria
Arrhythmogenic right ventricular dysplasia/cardiomyopathy is a clinical diagnosis with no single gold-standard test. The 2010 Task Force Criteria (TFC) is the standard for diagnosis today 82 ( Table 2) . It is a scoring system combining the six categories of disease features: right ventricular structural alteration, tissue characterization, repolarization abnormalities, depolarization abnormalities, arrhythmias, and family history. In each category, a major, minor, or no criterion can be met. Definite ARVD/C is diagnosed if an individual has at least 'four points' with a major criterion worth two points and one minor worth one point. A score of 'three points' is classified as probable ARVD/C. The criteria must come from different categories. The 2010 TFC is revised from the 1994 international task force guideline 83 with the addition of quantitative criteria of structural alterations and genetic testing. Its application has reduced the number of individuals satisfying the imaging criterion, increased the number of family Diagnostic and therapeutic strategies for ARVD/C members being diagnosed, and increased the overall diagnostic yield of ARVD/C compared with its 1994 counterpart. 84, 85 Although being the current gold standard, the 2010 TFC do not apply to leftdominant forms, 6 which will likely be included in future revisions. 
General diagnostic approach
When ARVD/C is suspected, the initial evaluation should include clinical inquiry about symptoms related to arrhythmia and heart failure, a detailed multi-generation family history, an exercise history, 12-lead ECG, ambulatory Holter monitoring, echocardiography, and cardiac magnetic resonance imaging (CMR). If the diagnosis remains inconclusive after this non-invasive approach, electrophysiological testing can be considered to characterize the arrhythmic substrate and stratify arrhythmic risk. 87, 88 Endomyocardial biopsy is rarely performed because of its invasiveness and poor sensitivity and specificity. Right ventriculography has been largely replaced by the echocardiography and CMR. Genetic testing is indicated for index patients with unequivocal phenotype and cascade screening of family members. 89 
Electrocardiography
The standard 12-lead ECG is rarely normal in ARVD/C patients. 90 It provides critical clues of the depolarization and repolarization abnormalities in ARVD/C. T-wave inversion from V1 to V3 in the absence of complete right bundle branch block is a major TFC criterion and the most common ECG finding 9,91 ( Figure 2) . T-wave inversion in V1 and V2 is a minor criterion. 82 Negative T waves may extend to V5 and V6, indicating severe structural abnormality and left-sided involvement. 92 Incomplete right bandle brunch block is seen in 15% of ARVD/C patients and T-wave inversions through V3 maintains optimal sensitivity and specificity in its presence. In the presence of complete right bandle brunch block, the most sensitive and specific diagnostic parameter is an r/s ratio <1. 91 It is important to recognize that the left dominant form of ARVD/C has a different ECG pattern than the more common right dominant form. Inverted T-waves can be confined to the (infero) lateral leads in left dominant form of ARVD/C. 93 Low precordial QRS voltage may be seen but are not included in the TFC. 93, 94 It can appear in advanced stage of the disease 95 and particularly in PLN mutation carriers. 96, 97 Epsilon waves are small amplitude deflections after the end of QRS but preceding the T wave. While epsilon waves are a major criterion for ARVD/C, we discourage their use when evaluating patients for ARVD/C. This reflects the fact that a recent study has shown very poor inter-reader reproducibility when panel experts were asked to identify Epsilon wave on ECG tracings of leads V1, V2, and V3. 98 Furthermore, this study revealed that epsilon waves do not impact the diagnosis of ARVD/C as they are only seen in patients with severe disease in whom the diagnosis is met on other structural and electrical criteria. 11, 98 In some difficult cases, Epsilon waves may be better observed with Fontaine lead system 99 or an insertable loop recorder. 100 Terminal activation delay, defined as duration from the nadir of S wave to the end of QRS > _55 ms, 101 is a minor criterion for depolarization abnormality. Although late potentials detected by signal-averaged eletrcocardiogram (SAECG) are also listed as a minor criterion for ARVD/C, 82 we have found them to have poor sensitivity and specificity relative to other criteria and have therefore abandoned performing SAECGs when evaluating patients for possible ARVD/C.
Ambulatory Holter monitoring
Ambulatory Holter monitoring captures premature ventricular complex and sustained or non-sustained ventricular tachycardia, both of which are important for diagnosis and follow-up in ARVD/C. 
Echocardiography
Echocardiography is the first line imaging tool when ARVD/C is suspected. Right ventricular wall motion abnormalities, ventricular dilation, and reduced systolic function are included in the 2010 TFC. 82 A RVOT long-axis diastolic dimension >30 mm occurred in 89% of probands and 14% of healthy controls. 104 Echocardiography has been used in clinical follow-up and showed marked variability in the rate of disease progression. 105, 106 However, more views than standard echocardiography are required to diagnose ARVD/C. Quantitative assessment of right ventricular function also requires high expertise but can lead to effective early detection of structural abnormalities 107 or even abnormal right ventricular deformation prior to structural abnormalities. 108 
Cardiac magnetic resonance
Cardiac magnetic resonance is the preferred imaging modality for ARVD/C 109 in experienced centres in the absence of an implantable cardioverter-defibrillator (ICD). It provides comprehensive information on structural, functional, and tissue characterization of the ventricles. As in echocardiography, only wall motion abnormality, ventricular dilation, and systolic dysfunction are included in the 2010 TFC. 82 Microaneurysm is not a criterion due to the concern of overuse of this term leading to false positive diagnoses. Although the presence of late gadolinium enhancement on CMR has been shown to be a diagnostic feature of ARVD/C and correlates with the myocardial fibro-fatty changes, 110 this MRI parameter was not included in the 2010 Diagnostic Criteria. Despite this, we believe that it is of diagnostic value, especially those with the biventricular or left dominant forms. Myocardial fat and wall thinning are not diagnostic for ARVD/ C either. 111 Nevertheless, tissue characterization on CMR deserves recognition and combining them to the 2010 TFC may improve diagnostic accuracy. 112 The location of wall motion abnormalities was not addressed in the 2010 TFC. Although the right ventricular apex is part of the initial report describing the triangle of dysplasia, 2 it is not typically affected in isolation. Instead, the basal inferior and anterior right ventricle, and the posterolateral left ventricle are commonly affected. 113 Common normal variants mischaracterized as ARVD/C include right ventricular free wall tether, pectus excavatum, and isolated apicolateral bulge 111 ( Figure 3) . It is important to recognize that MR imaging is not the gold standard for diagnosis of ARVD/C but is only one of a number of diagnostic tests that should be considered when evaluating patients for suspected ARVD/C. In healthcare systems where CMR is not easily accessible, echocardiography in experienced hands using multiple views (with or without contract medium or deformation imaging) can still very valuable.
Diagnostic and therapeutic strategies for ARVD/C
Family history and genetic testing
Arrhythmogenic right ventricular dysplasia/cardiomyopathy is most commonly characterized by autosomal dominant inheritance with reduced penetrance. As a result, a definite diagnosis in first-degree family members is considered as a major criterion, even when no pathological mutation is detected in the family. 82 According to a recent study, one third of first-degree relatives develop ARVD/C with siblings having the highest risk of disease. 114 Genetic testing has been incorporated into the 2010 TFC. Genetic counselling and genetic testing is recommended for making the diagnosis in probands and as part of cascade screening of family members of probands with mutations. 115 Mutations are detected in approximately 60% of index patients so the absence of mutations does not exclude the diagnosis. 78 Genetic testing is recommended to identify pathologic mutations in probands fulfilling phenotypic criteria and facilitate cascade screening of family members. 18 The population prevalence of ARVD/C related mutations is unclear. A recent population-based study showed no phenotype in cases with definite loss of function desmosomal variants. 116 Therefore, genetic testing is not recommended in individuals with only one minor 2010 TFC criterion and may be considered when one major or two minor criteria being meet. 117 Given the complexity in result interpretation and the rapid-evolving nature of genetics in ARVD/C, genetic counselling is strongly advised for patients and family members. 118 
Endomyocardial biopsy
The tissue characterization criteria in 2010 TFC focused on the severity of myocyte loss and specified the quantitative parameters of fibrosis. 82 However, endomyocardial biopsy is invasive and its diagnostic sensitivity may be limited due to the patchy distribution of the disease. Although the right ventricular free wall is often affected, biopsy is usually taken from the septum for fear of perforation, which further limits its sensitivity. 45 Immunohistochemical analysis of desmosomal protein localization is not specific for ARVD/C because similar disease patterns can also be seen in sarcoidosis and giant cell myocarditis. 119 Today, endomyocardial biopsy is rarely performed.
Its diagnostic value in ARVD/C is mainly for excluding other cardiomyopathies, myocarditis, and sarcoidosis.
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Isoproterenol testing
Due to the high prevalence of catecholamine-facilitated ventricular tachycardia in ARVD/C, 120 ventricular arrhythmogenicity during isoproterenol testing has been proposed to assist diagnosis. 121 In the article by Denis et al., 121 isoproterenol is infused continuously for 3 min at 45 lg/min. The test is considered positive if polymorphic premature ventricular contractions with at least 1 couplet or ventricular tachycardia of left bundle branch pattern but excluding RVOT origin is induced. Its sensitivity, specificity, positive, and negative predictive values to diagnose ARVD/C are 91.4%, 88.9%, 43.2%, and 99.1%, respectively. Although it is not included the 2010 TFC, its high sensitivity may help improve diagnosis in early disease stage. The high dose isoproterenol challenge is also being evaluated as a risk predictor in ARVD/C.
Differential diagnosis
The common differential diagnoses for ARVD/C are idiopathic ventricular tachycardia and sarcoidosis. 11 Other conditions to consider include dilated cardiomyopathy, pulmonary hypertension, and Uhl's disease. Idiopathic ventricular tachycardia, either from RVOT or aortic sinus cusp, is usually associated with normal ECG and echocardiogram. 122 A scoring system combining T-wave inversions in V1-V3, QRS duration in lead I > _120 ms, QRS notching, and late precordial transition effectively distinguish idiopathic RVOT ventricular tachycardia from ARVD/C. 123 Ectopic QRS morphology (intrinsicoid deflection time >80 ms, QS pattern in lead V1, and QRS axis >90 ) has been reported recently to aid in differentiating idiopathic RVOT ventricular tachycardia from early ARVD/C. 124 Exhaustive work up is not needed when ECG and echocardiograph are normal and family history is negative for sudden death. Cardiac sarcoidosis can overlap with ARVD/C. Older age of symptom onset, presence of cardiovascular comorbidities, non-familial pattern of disease, signs of conduction defect, significant left ventricular dysfunction, myocardial delayed enhancement of the septum, first degree or higher degrees of atrio-ventricular (AV) block, and mediastinal lymphadenopathy should raise the suspicion for cardiac sarcoidosis. 125 Cardiac position emission tomography can be very important for differential diagnosis. 126 Endomyocardial biopsy may be required to assist the diagnosis. Biventricular ARVD/C with severe left side involvement may mimic dilated cardiomyopathy. Dilated right ventricle can also be seen in congenital heart disease such as Ebstein anomaly, Uhl's disease, anomalous venous return, pulmonary hypertension, or right ventricular infarction. 11 
Management of arrhythmogenic right ventricular dysplasia/ cardiomyopathy
The clinical management of ARVD/C patients consists of six aspects: (i) establishing an accurate diagnosis; (ii) risk stratification for sudden death; (iii) prevention of sustained ventricular arrhythmia; (iv) prevention of development of heart failure; (v) cardiac transplant; and (vi) screening and follow-up of family members. We will discuss each of this six-pronged approach here.
Establishing an accurate diagnosis
An accurate diagnosis is the premise of management. As above, lack of awareness of 2010 TFC and misinterpretation of CMR are the most common reasons for misdiagnosis.
Risk stratification for sudden death and decision for an implantable cardioverterdefibrillator
The prognosis of ARVD/C is predominantly related to ventricular arrhythmia which may lead to sudden death. 78 Its estimated overall mortality varies from 0.08% per year to 3.6% per year. 82, 127 Although not tested in randomized controlled trials, the efficacy of ICD therapy has been established by multiple observational studies. 7, 67, [128] [129] [130] Between 40% and 78% of patients received appropriate ICD interventions after implantation. The survival benefit was estimated at 26%. 128 However, the benefit comes at the expense of device/leadrelated complications (3.7% per year) and inappropriate ICD interventions (4.4% per year). 1, 102 Therefore, assessing sudden death risk is central in the disease management.
Commonly recognized predictors of life-threatening arrhythmia are summarized here. The strongest predictors are prior cardiac arrest from ventricular fibrillation and sustained ventricular tachycardia. 45 Other major risk factors include arrhythmogenic syncope, nonsustained ventricular tachycardia, and severe systolic dysfunctions of the right, left, or both ventricles. 45, 18 Premature ventricular complex count >1000 per day, T-wave inversion more than three leads, male sex, younger age at presentation, and proband status are minor risk factors. 1 Inducibility at electrophysiology study has been associated with ventricular arrhythmia treated by ICD from the Johns Hopkins and the Zurich experience 67, 102, 130, 131 but not in other studies. 128, 132 Atrial fibrillation may reflect electrical instability and has been associated with life-threatening arrhythmic events. 66 Risk of ventricular arrhythmia does not seem to significantly increase during pregnancy. 133 Unwillingness to restrict exercise has also been associated with higher risk of ventricular arrhythmia, 17, 62 The absence of risk factors confers a low risk of sudden death (<1% per year) and ICD is not indicated. Diagnostic and therapeutic strategies for ARVD/C patient's preferences and values. Whereas some patients are unwilling to accept even a small risk of sudden death and consider placement of an ICD to be reassuring, other patients are adamantly against having an ICD implanted and are willing to accept a small risk of sudden death. Single-chamber ICDs are recommended to minimize the risk of long-term lead-related complications especially in young patients. Although the number of inappropriate interventions may be decreased by a dual-chamber detection system, the additional lead predisposes to a higher risk of short and long term complications and should be only be employed in the setting of symptomatic bradycardia or AV block (which is virtually never seen in patients with ARVD/ C). 45 Anti-tachycardia pacing is highly successful in terminating ventricular arrhythmia and should be programmed in all devices. 132 The role of subcutaneous ICD is under investigation.
Prevention of sustained ventricular arrhythmias
Pharmacologic therapy is commonly utilized in the management of ARVD/C despite the lack of randomized clinical trials. Beta-blockers are recommended as the first line therapy for all definite ARVD/C patients. 1 This recommendation is an extrapolation of the betablockers' efficacy in sudden death prevention in heart failure. 134 It also relies on the observations that ventricular arrhythmia in ARVD/ C is often effort-related and catecholamine-facilitated. 120 The use of anti-arrhythmic drugs rarely eliminates the risk of sudden death 45 and is mainly to reduce the arrhythmia burden. 1 If betablocker is ineffective, the conventional 'wisdom' is to try sotalol followed by amiodarone. However, evidence from cases series regarding the efficacy of sotalol and amiodarone have been conflicting. 135, 136 The addition of flecainide to beta-blockers may be effective according to a recent case series. 137 Overall, the use of antiarrhythmic drugs is empirical. The field is awaiting well-designed clinical trials to guide the use of anti-arrhythmic drugs in ARVD/C management. Catheter ablation is reserved for ARVD/C patients who fail pharmacologic therapies and continue to have frequent sustained or symptomatic non-sustained ventricular arrhythmias. 1 According to the 2015 Treatment Consensus, ARVD/C patients with incessant ventricular tachycardia (VT) or frequent ICD interventions on VT despite maximal pharmacological therapy should be referred for catheter ablation (Class I indication). 1 Despite a high short-term success rate, the major limitation of catheter ablation is the recurrence of sustained ventricular arrhythmias in 50-70% of patients' after 3-5 years of follow-up. [138] [139] [140] [141] Epicardial VT ablation or a combined endo-epi approach has been associated with improved short and long term efficacy with a 30% recurrence rate at 2 years of follow up. 138 New arrhythmogenic foci created by the progression of fibrofatty production may explain the not insignificant recurrence rate. 140 Nevertheless, catheter ablation is still an important palliative procedure to improve patients' quality life by reducing the arrhythmia burden. Bilateral sympathectomy may be considered for refractory ventricular arrhythmias. 142 Exercise restriction is recommended to all affected patients and desmosome mutation carriers. 1 This is because that exercise has been associated with development and severity of the ARVD/C phenotype both in animal 61, 46 and human studies 17, 62, 63, 143 ( Figure 5) .
Importantly, continuing to participate in competitive sports after diagnosis was associated with higher risk of ventricular tachyarrhythmia in definite and borderline ARVD/C probands. 62 Desmosomal mutation carriers who remained in the top quartile of exercise duration after presentation had the higher risk of incident ventricular arrhythmia.
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Prevention of progression and development of heart failure Few studies have examined structural progression in ARVD/C. It has been shown that structural dysfunction of the disease is progressive but with substantial interpatient variability. 105 As noted above, exercise restriction is believed to slow the disease progression. Because of the proven efficacy of angiotensin-converting enzyme inhibitors in heart failure, it has also been used for most patients with ARVD/C especially in the presence of structural changes. 1 
Cardiac transplantation
Heart transplant is rarely needed in ARVD/C and is the last resort in case of either end-stage heart failure or debilitating lethal arrhythmia. 80 Patients requiring transplant often have disease onset at a younger age. Cardiac transplantation, when needed, is generally performed 10-20 years after initial presentation. Overall, the survival of patients with ARVD/C at 1, 5, and 10 years is 87%, 81%, and 77%, similar to non-ARVD/C recipients and better than ischaemic cardiomyopathy. 144 
Screening approach to family members
After a proband is diagnosed with ARVD/C, there are three scenarios applicable to family members: (i) presence of a pathological mutation; (ii) absence of a pathological mutation, and (iii) presence of a variant of uncertain significance. 45 In the presence of a pathological mutation, mutation-specific 'cascade' genetic testing is recommended to identify mutation-carrying family members. 18 Non-carriers are unlikely to develop the disease. For family members with disease-causing mutations, serial examination at one to three year intervals starting at the age of 10 years and exercise restriction are recommended. 17 This serial screening should consist of an ECG, a Holter, and a CMR or echocardiogram. In the absence of a pathological mutation, ARVD/C is still considered hereditary and all family members are recommended to undergo diagnostic testing at 1-3 years intervals. When a variant of uncertain significance is identified, phenotyping of all at-risk relatives remains important and cascade genetic screening should not be performed to assist in clinical management (although it may assist in refinement of variant classification). Again, genetic counselling is strongly recommended in the management of ARVD/C. 118 
Direction for future research
Over the past three decades, much has been learned about diagnosis and treatment of ARVD/C. The complexity of the disease and advance in technology create tremendous opportunities to advance the care we deliver to these patients. Better delineation of the disease progression will deepen the understanding of its natural history and facilitate early diagnosis. As data interpretation catches up with the explosion of sequencing technology, we will have a better insight into its genetic aspect. Detailed and objective measurement of Diagnostic and therapeutic strategies for ARVD/C exercise exposure with prospective follow-up will make the personalized recommendation on exercise restriction possible. The refinement of risk stratification for sudden death will enable clinicians to implant an ICD in the right patients. Basic mechanistic research is needed in the search of curative therapy for the disease. At the end of the day, promising therapies will need to be tested in randomized controlled trials. Because ARVD/C is a rare disease, institutional and international collaboration will be required for these exciting endeavours.
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